Supplementary Figure 3 from Phase II, Randomized Study of Spartalizumab (PDR001), an Anti–PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer

Authors :: Darren W-T. Lim
Luigi Manenti
Romain Séchaud
Jennifer Mataraza
Hongzi Liang
Yao Yao
Sebastian Szpakowski
Juan Gonzalez-Maffe
Steven McCune
Joël Guigay
Ammar Sukari
Alexander I. Spira
Zujun Li
Pei-Jen Lou
Victor H.F. Lee
Suebpong Tanasanvimon
Brigette B.Y. Ma
Somvilai Chakrabandhu
Po Chung Chan
Chia-Jui Yen
Li Zhang
Arunee Dechaphunkul
Roger K-C Ngan
Shau-Hsuan Li
Hung-Ming Wang
Caroline Even
Publication Year :: 2023
Publisher :: American Association for Cancer Research (AACR), 2023.
Abstract: Supplemental Figure S3. Best percentage change from baseline in sum of diameters of target lesions for patients treated with spartalizumab (A) and chemotherapy (B)

Tools